Devices › Intracranial neurovascular stent
Device brand name · Stent intracranial neurovascular
Wingspan Stent: medical device reports filed with FDA
163 reports name it, 2009–2012. Manufacturer given most often on reports: Boston Scientific - Fremont. Product code NJE.
- 163
- device reports naming the brand
- 0% of all MAUDE reports · about 10 a year
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 14.7%
- classified as malfunction
- 56.2% across the product code
- 16.6%
- classified as death, as reported
- 27 reports · not verified by FDA
FDA's MAUDE database holds 163 reports that name the brand "Wingspan Stent" (stent intracranial neurovascular), received between October 2009 and October 2012; the manufacturer given most often on reports is Boston Scientific - Fremont. Spellings of one product vary from report to report.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (68.1%), death (16.6%) and malfunction (14.7%); across all intracranial neurovascular stent reports (product code NJE) death is recorded in 6.8% and malfunction in 56.2%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are premature activation (6.1%), activation, positioning or separation problem (5.5%) and break (2.5%). The patient problems coded most often are stroke/cva, stenosis and death. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
No report naming Wingspan Stent was received in the five years to August 2026; the latest was received in October 2012.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 7,916 reports carrying product code NJE. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Premature activation | 10 | 6.1% | 22.7% |
| Activation, positioning or separation problem | 9 | 5.5% | 2.3% |
| Breakthe device broke | 4 | 2.5% | 2.7% |
| Occlusion within devicethe device blocked | 4 | 2.5% | 1.6% |
| Material separation | 3 | 1.8% | 1.2% |
| Insufficient device problem information | 2 | 1.2% | 0.3% |
| Migration or expulsion of device | 2 | 1.2% | 2.1% |
| Device contamination with chemical or other material | 1 | 0.6% | 0% |
| Difficult or delayed positioning | 1 | 0.6% | 1% |
| Difficult to advance | 1 | 0.6% | 1.1% |
| Material rupture | 1 | 0.6% | 0% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Stroke/cva | 36 | 22.1% |
| Stenosis | 34 | 20.9% |
| Deaththe patient died; cause not stated by this term | 16 | 9.8% |
| Neurological deficit/dysfunction | 15 | 9.2% |
| Thrombosis | 13 | 8% |
| Transient ischemic attack | 12 | 7.4% |
| Hemorrhage, cerebral | 10 | 6.1% |
| Intracranial hemorrhage | 10 | 6.1% |
| Hemorrhage, subarachnoid | 8 | 4.9% |
| Infarction, cerebral | 7 | 4.3% |
| Thrombus | 7 | 4.3% |
| Occlusion | 6 | 3.7% |
| Vascular dissection | 6 | 3.7% |
| Disability | 4 | 2.5% |
| Hematomaa collection of blood under the skin or in tissue | 2 | 1.2% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Wingspan Stent | Product code NJE | All MAUDE reports |
|---|---|---|---|
| Reports | 163 | 7,916 | 26,136,888 |
| Share of that pool | — | 2.1% | 0% |
| Classified as death, per 1,000 reports | 166 | 68 | 9 |
| Classified as injury | 68.1% | 36.8% | 36.2% |
| Classified as malfunction | 14.7% | 56.2% | 62.3% |
| Filed by the manufacturer | 100% | 99.3% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code NJE
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Cerenovus Enterprise | 1,543 | 951 | 0.5% |
| Enterprise Vascular Reconstruction Device And Delivery System | 1,509 | 0 | 7.6% |
| Stent - Vascular Reconstruction | 398 | 3 | 9% |
| Wingspan Stent System | 281 | 0 | 24.9% |
| Unknown_Neurovascular_Product | 1,062 | 48 | 12.9% |
| Enterprise2 4mmx23mm | 208 | 1 | 0.5% |
| Neuroform Atlas 3 0mm X 21mm No Tip - Ce | 247 | 93 | 0% |
| Neuroform Atlas 3 0mm X 15mm No Tip - Ce | 160 | 41 | 1.9% |
| Codman | 183 | 0 | 1.6% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Wingspan Stent reports
How many FDA reports name Wingspan Stent?
163 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
injury (68.1%), death (16.6%) and malfunction (14.7%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
premature activation (6.1%), activation, positioning or separation problem (5.5%), break (2.5%), occlusion within device (2.5%) and material separation (1.8%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Wingspan Stent was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.